Barry Greene joins Dyne Therapeutics (DYN) board with new option grant
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Dyne Therapeutics appointed Barry E. Greene to its Board of Directors as a Class I director, with a term running until the 2027 annual meeting and continuation until a successor is elected or earlier departure.
The Board determined that Greene is an independent director under Nasdaq rules. Upon joining, he received a stock option for 57,463 shares at an exercise price of $20.87 per share, vesting in equal monthly installments over three years, with full acceleration upon a change in control. He will also receive $45,000 in annual cash compensation, additional annual equity grants under the non-employee director compensation program, and reimbursement of reasonable expenses related to Board meetings.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Director stock option grant: 57,463 shares
Option exercise price: $20.87 per share
Vesting period: 3 years
+1 more
4 metrics
Director stock option grant
57,463 shares
Option to purchase common stock granted upon Board election
Option exercise price
$20.87 per share
Closing price of common stock on grant date
Vesting period
3 years
Option vests in equal monthly installments over three years
Annual cash retainer
$45,000
Yearly cash compensation as a member of the Board
Key Terms
independent director, 2020 Stock Incentive Plan, change in control, indemnification agreement
4 terms
independent director financial
"The Board has determined that Mr. Greene is an “independent” director under the Nasdaq Stock Market rules."
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
2020 Stock Incentive Plan financial
"he received, under the Company’s 2020 Stock Incentive Plan, an option to purchase 57,463 shares"
change in control financial
"In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
indemnification agreement financial
"Mr. Greene will enter into the Company’s standard form of indemnification agreement."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
FAQ
What did Dyne Therapeutics (DYN) announce about its Board of Directors?
Dyne Therapeutics added Barry E. Greene as a Class I director to its Board. He will serve until the 2027 annual meeting and continue until a successor is elected or he departs earlier, strengthening the company’s governance structure with another independent board member.
Is Barry E. Greene considered an independent director at Dyne Therapeutics (DYN)?
Yes, the Board determined that Barry E. Greene qualifies as an independent director under Nasdaq rules. This designation means he meets specific criteria regarding relationships and affiliations, supporting objective oversight of management and alignment with recognized corporate governance standards.
What equity compensation will Barry E. Greene receive from Dyne Therapeutics (DYN)?
Upon election, Barry E. Greene received an option to purchase 57,463 Dyne Therapeutics common shares at $20.87 per share. The option vests in equal monthly installments over three years and fully accelerates if there is a change in control of the company.
What cash compensation will Barry E. Greene earn as a Dyne Therapeutics (DYN) director?
As a Board member, Barry E. Greene will receive annual cash compensation of $45,000. He will also receive annual equity grants under the non-employee director compensation program and reimbursement for reasonable travel and out-of-pocket expenses related to attending Board meetings.
What happens to Barry E. Greene’s Dyne Therapeutics (DYN) stock options if there is a change in control?
If Dyne Therapeutics undergoes a change in control, the vesting of Barry E. Greene’s stock option accelerates in full. This means all unvested option shares would become fully exercisable at that time, instead of continuing on the monthly vesting schedule.